ERBB2 and breast cancer: In a study of about 171,881 breast cancer patients, 84% had IDC; of these, 82% were ER-positive, 72% were PR-positive, and 84% were HER2-negative, confirming that IDC is the most common invasive breast cancer, with Luminal A accounting for the majority of the tumors [55].